ABSTRACT The clinical efficacy and safety of transvenous cardioversion for termination of sustained ventricular tachycardia (VT) were examined by a prospective randomized study design in 22 patients (19 men, three women; mean age 64 ± 9 years) with organic heart disease and sustained VT. Patients were randomly assigned to undergo an incremental low-energy protocol from 0.03 to 2.2 J (group A, 11 patients) or an incremental high-energy protocol from 0.5 to 10.0 J (group B, 11 patients). Transvenous cardioversion was performed during electrophysiologic studies in the control (drug-free) state and during serial antiarrhythmic drug testing in all patients. Both groups were comparable for demographic, disease and functional status, and electrophysiologic parameters. A total of 77 episodes of VT (group A, 45; group B, 32) were analyzed. The overall efficacy of transvenous cardioversion for termination of VT was 62% (group A 56% vs group B 72%; p < .01). Antiarrhythmic drug therapy did not significantly enhance efficacy of transvenous cardioversion (control 59% vs drug 65%; p > .2).
transvenous cardioversion with two different incremental energy protocols in unselected patients with recurrent and sustained VT.
Methods
Patients. All patients entering this study satisfied the following selection criteria: (1) Patients had recurrent sustained VT and were undergoing clinically indicated electrophysiologic procedures. For this study, "recurrent" was defined as three or more spontaneous episodes and "sustained" as VT of greater than 30 sec duration or requiring earlier electrical or pharmacologic termination for hemodynamic compromise; (2) absence of recent (less than 30 days) myocardial infarction; (3) reproducible induction of sustained VT during electrophysiologic studies; and (4) written informed consent to undergo transvenous cardioversion.
Twenty-two patients satisfied all inclusion criteria. There were 19 men and three women, mean age 64 + 9 years. All patients had organic heart disease, with a mean left ventricular ejection fraction of 31 %. Coronary artery disease was present in 18 patients and cardiomyopathy in four patients.
Catheter and cardioversion system. The cardioversion lead was a No. 9.5F Medtronics 6880 temporary electrode catheter. This is a tripolar catheter with distal and intermediate electrodes, each with a surface area of 1.25 cm2 separated by an interelectrode distance of 5 mm. These electrodes were positioned in the right ventricular apex and were used for sensing the ventricular electrogram and for bipolar ventricular pacing. During cardioversion both became electrically common, forming the cathode. The two proximal electrodes, each 1.25 cm' in surface area, were also separated by 5 mm and were 125 mm proximal to the distal electrode pair. These were usually located at the superior vena cava-high right atrial junction, were common, and formed the anode during cardioversion. Lead position was verified by fluoroscopy at the time of electrophysiologic study. The electrodes were connected by three coil-wound, multifilar, drawn brazed-strand, low-impedance, wire electrical conductors in a coaxial configuration to three connector pins. The conductors were insulated by sleeves of polyurethane. The connector pins at the proximal end of the catheter were connected by a cable to a Medtronics model 5350 external cardioverterdefibrillator. This device is a battery-operated generator capable of delivering graded energy shocks when the storage capacitor is discharged. It has sensing capabilities, allowing shocks to be synchronized with the sensed electrogram. The energy output ranges from 0.03 to 28.0 J. Three different waveforms controlled by tilt settings can be selected. The cardioverter can also be interfaced with a programmed stimulator by an external input that connects directly to the distal catheter electrodes for performance of programmed electrical stimulation and/or bipolar pacing.
Study design. Patients were prospectively randomized to undergo one of two incremental transvenous cardioversion protocols. Group A patients entered a low-energy protocol consisting of eight specified incremental shocks ranging from 0.03 to 2.2 J (0.03, 0.05, 0.06, 0.11, 0.27, 0.56, 1. 1, and 2.2). Group B patients entered a high-energy protocol with six specified incremental shocks ranging from 0.5 to 10.0 J (0.5, 1.0, 1.5, 2.0, 5.0, and 10.0). Groups A and B included 11 patients each, all of whom completed the entire study protocol.
After randomization, patients underwent initial electrophysiologic studies in the control, drug-free state. All patients were studied in the nonsedated, postabsorptive state. Multipolar catheters were inserted by standard percutaneous introduction techniques as previously described. l Intracardiac electrograms were usually monitored at high and mid-right atrium, His bundle, and right ventricular apex. Surface electrocardiographic leads I, aVF, and V, were recorded simultaneously with intracardiac electrograms. Arterial blood pressure was monitored with an indwelling femoral arterial sheath connected to a Statham P23 transducer. A multichannel display recorder (Electronics for Medicine VR-12, White Plains, NY) was used to amplify and display the electrograms. Hard-copy recordings were obtained at paper speeds of 50 to 250 mm/sec. All records were stored on magnetic FM tape. Programmed electrical stimulation was performed with a custom-made programmed stimulator (Bloom Associates, Ltd., Narbeth, PA), which delivered rectangular pulses of 1 or 2 msec duration at twice diastolic threshold. Programmed stimulation was performed with a standard protocol for our laboratory as previously described.
After sustained VT was induced, immediate transvenous cardioversion was attempted with the preselected protocol. The protocol was terminated if successful transvenous cardioversion of VT was achieved or if VT accelerated or degenerated into ventricular fibrillation (VF). Unsuccessful transvenous cardioversion was defined as inability to terminate VT at the highest energy level in a particular protocol or if VT accelerated or degenerated into VE. shock. One patient had transient slowing with change in QRS morphology from left bundle branch block to right bundle branch block before termination (figure iB). Only two of 48 (4%) successful cardioversions displayed transient acceleration before cardioversion (figure IC). Figure 2 shows data from catheter endocardial mapping performed during a transvenous countershock. This 5 J shock depolarized both ventricles, reset the tachycardia circuit, which slowed, and changed ventricular activation pattern and QRS complex morphology before termination.
Complications of transvenous cardioversion Acceleration of VT or degeneration into VF. Twenty-four (8%) of all transvenous cardioversion shocks resulted in sustained acceleration of VT (figure 3). However, 31% of all episodes of VT accelerated during the course of a particular cardioversion protocol. Seventysix percent of all failed transvenous cardioversion protocols in groups A and B were terminated because of acceleration of VT. Shocks were synchronized with the QRS complex in all instances. They also noted acceleration of VT and degeneration into VF in one patient. Yee et al.9 used a conventional defibrillation unit providing a damped sinusoidal discharge waveform and higher countershock energies ranging from 2.5 to 40 J. Although they were able to terminate 87% of episodes of VT with this technique, four of the six patients studied experienced both successful and failed transvenous cardioversion. Therefore, although unc ontrolled studies in small groups of patients suggest that transvenous cardioversion is valuable in termination of VT, a controlled prospective trial to determine its clinical efficacy and safety is currently unavailable. In addition, the factors underlying successful and failed cardioversion are currently unknown. This study was designed to clarify these issues.
Clinical efficacy. The overall efficacy of transvenous cardioversion in this prospective study was moderate (62%) in unselected patients with VT. This is comparable to the findings of a prior report by Waspe et al. ,'0 but is substantially lower than the results of some other reports.7 1 The differences in efficacy rate are clearly 576 explained by the unselected controlled study design and larger experience in this report as compared with selected patients in the prior reports. Additionally, an analysis of factors influencing efficacy of this technique can account for different efficacy rates. VT cycle length is a major determinant of efficacy. Longer VT cycle lengths are associated with greater efficacy. The mean VT cycle length in the successfully cardioverted patients was significantly longer than that in the patients who could not be cardioverted in this study (316 ± 70 vs 265 ± 51 msec, respectively; p < .0005). Similar observations were noted by Waspe et al. 10 in a smaller number of patients studied in an uncontrolled energy protocol ranging from 0.01 to 5.0 J. VT cycle length exceeded 400 msec in 68% of episodes of VT reported by Zipes et al.7 This is substantially longer than the value in the present report (mean VT cycle length, 289 ± 59 msec) and could alone account for different efficacy rates. Similar information is unavailable in the report from Yee et al. 9 Our observations indicate that the absolute cardioversion shock energy is another important factor in determination of efficacy. Episodes of VT treated with the high-energy protocol had significantly greater mean energy delivered per shock and consequently greater efficacy. Yee et al.9 used energies ranging from 2.5 to 40 J and noted an efficacy rate of 65% when the energy delivered was below 5 J, quite similar to the rate in this study. However, energies up to 40 J increased the overall efficacy rate to 87%. Since patient tolerance for the cardioversion shock becomes a major factor in determining the clinical application of this technique, increasing efficacy rates at increasing energy levels were analyzed in this study. that at energies up to 0. observations is a prior report that did not note a relationship of efficacy to the timing of cardioversion shock. '0 However, the onset of cardioversion attempts in that study was somewhat later (43 sec), comparable to our failed cardioversion attempts. In addition, the ventricular function of the patient population in their study (mean left ventricular ejection fraction 40%) was somewhat better than that in our patients.
The intraventricular conduction pattern in sinus rhythm differed in the successful and failed cardioversion groups, being significantly better in the former. Although this has not been previously analyzed, better intraventricular conduction may enhance efficacy of the cardioversion shock by improved and rapid penetration of critical components of the VT circuit.
Safety. Acceleration of VT during failed transvenous cardioversion remains the major safety problem in the clinical application of this technique. Although the potential of acceleration for an individual shock is low, the use of a series of incremental shocks, as is general clinical practice for transthoracic cardioversion, markedly increases the frequency of this problem. Cardioversion protocols for 31% of all episodes of VT were terminated because of this complication. However, the incidence was higher in the absence of antiarrhythmic drugs (32%) as compared with that observed with drugs (23%). Antiarrhythmic therapy also increased the mean energy at which accleration of VT was observed. Although the wide variety of antiarrhythmic agents used precludes a useful comparative analysis, the electrophysiologic effects of these agents may provide partial protection against this complication.
Lead complications were infrequent in this study. The incidence of displacement of electrode catheters was low (3%) in this and other studies, but active fixation electrodes may be considered to eliminate this problem. Prolonged use of the catheter also appears to be feasible. The catheter electrode system was easily inserted, and electrode location with the 125 mm spacing was usually appropriate in this study group. Early experience with a similar electrode catheter with tines for long-term implantation appears favorable. '3 The incidence of postcardioversion arrhythmias is substantial and merits analysis. Transient supraventricular arrhythmias were common and usually hemodynamically insignificant. Rarely, sustained supraventricular arrhythmias resulted and necessitated treatment. Early experience with a prototype implantable unit indicates that these arrhythmias can trigger automatic detection algorithms in an implanted device.'3 However, the occurrence of bradyarrhythmias is more disturbing. The incidence of this complication is significant (23%) and although it is usually transient, asystole was observed after one episode of VT. This implies the need for availability of demand pacing capability whenever this technique is used. Yee et al. 9 observed that catheter countershocks can abruptly increase pacing thresholds and decrease R wave amplitude at the same site as the countershock. ' Therefore the catheter electrodes used for countershock may not be acceptable for immediate backup demand pacing. However, pacing threshold when measured shortly after transvenous cardioversion returns to baseline as seen in this study. ing to terminate sustained VT in a retrospective analysis of 23 patients. Although the efficacy rate of this technique was high (89%), acceleration of VT was observed infrequently (4% incidence per burst). Comparison of this technique with transvenous cardioversion merits examination. A comparative trial performed in our laboratory with a prospective randomized crossover study design has demonstrated comparable efficacy of the two techniques (transvenous cardioversion 83%, rapid ventricular pacing 80%; p > .2). '6 The incidence of acceleration of VT was also comparable (transvenous cardioversion 7% per shock, rapid ventricular pacing 2% per burst; p > .2). Patient tolerance was clearly better and the incidence of postcardioversion arrhythmias was significantly lower (incidence 3%) with rapid ventricular pacing. Furthermore, data analysis indicates a high degree of overlap in the efficacy of these techniques, suggesting that both techniques are competitive and not complementary.
Conclusions. The results of this prospective study indicate that transvenous cardioversion has limited efficacy for termination of VT in unselected patients. Both intrinsic factors, related to the patient and the tachycardia, and extrinsic factors, related to the energy shock, influence efficacy. Careful selection of patients and the energy of countershock with respect to these factors will enhance the efficacy of this technique. Although antiarrhythmic drugs may increase the safety of the technique, the potential hazard of acceleration of VT requires availability of defibrillation capabilities whenever the technique is used. The occurrence of postcardioversion bradyarrhythmias may warrant the need for a backup demand pacing system. Current lead systems may be clinically applicable for short-term use. However, comparison with a currently available alternative for electrical termination of VT has not demonstrated clear advantages of this technique and indicates potentially limiting untoward effects for short-and long-term use.
